Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021)
Humacyte (HUMA) reported Preferred Stock Liabilities of $421.0 million for Q2 2021, little changed quarter-over-quarter from $421.0 million in Q1 2021.
Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Humacyte (HUMA) has 2 years of Preferred Stock Liabilities data on file, last reported at $421.0 million in Q2 2021.
- Preferred Stock Liabilities for Q2 2021 came in at $421.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $421.0 million (changed N/A YoY), and the FY2020 annual result was $421.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $421.0 million in Q2 2021 per HUMA's latest filing, from $421.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $421.0 million in Q3 2020 and troughed at $421.0 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 420.99 Mn |
| Mar 31, 2021 | 420.99 Mn |
| Dec 31, 2020 | 420.99 Mn |
| Sep 30, 2020 | 420.99 Mn |